Cargando…
Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
Autores principales: | Gulácsi, László, Brodszky, Valentin, Baji, Petra, Rencz, Fanni, Péntek, Márta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427141/ https://www.ncbi.nlm.nih.gov/pubmed/28447267 http://dx.doi.org/10.1007/s12325-017-0538-3 |
Ejemplares similares
-
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
por: Gulácsi, László, et al.
Publicado: (2017) -
Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data
por: Brodszky, Valentin, et al.
Publicado: (2017) -
Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
por: Brodszky, Valentin, et al.
Publicado: (2014) -
Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies
por: Zrubka, Zsombor, et al.
Publicado: (2019) -
Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data
por: Baji, Petra, et al.
Publicado: (2020)